About Nanopath
Nanopath is a company based in Cambridge (United States) founded in 2019 by Alison Burklund and Amogha Tadimety. Nanopath has raised $10 million across 5 funding rounds from investors including NIH, Norwest Venture Partners and National Science Foundation. Nanopath offers products and services including Molecular Diagnostic Platform. Nanopath operates in a competitive market with competitors including N-of-One, OrigiMed, Range Bio, Coral Genomics and VSense, among others.
- Headquarter Cambridge, United States
- Founders Alison Burklund, Amogha Tadimety
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nanopath Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$10 M (USD)
in 5 rounds
-
Latest Funding Round
$5.34 M (USD), Debt – Conventional
Jan 24, 2025
-
Investors
NIH
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nanopath
Nanopath offers a comprehensive portfolio of products and services, including Molecular Diagnostic Platform.
Enables scalable point-of-care testing for disease diagnosis.
Funding Insights of Nanopath
Nanopath has successfully raised a total of $10M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $5.34 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nanopath
Nanopath has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Norwest Venture Partners and National Science Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and growth equity firm providing investments and resources to entrepreneurs in various sectors.
|
Locked | Locked | Locked | |
|
Venture capital fund focused on early-stage healthcare startups
|
Locked | Locked | Locked | |
|
Capital is provided to women-led ventures in early stages.
|
Locked | Locked | Locked |
Investor details for Nanopath
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nanopath
Investment portfolio details for Nanopath
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nanopath
Detailed financials for Nanopath
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nanopath Comparisons
Peer comparison for Nanopath
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nanopath
Nanopath operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as N-of-One, OrigiMed, Range Bio, Coral Genomics and VSense, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Molecular profiles are analyzed for clinical decision support in oncology.
|
|
| Locked | Locked | Locked |
Genetic sequencing is utilized for personalized cancer diagnostics and counseling.
|
|
| Locked | Locked | Locked |
Provider of solutions for health monitoring based on translational proteomics
|
|
| Locked | Locked | Locked |
Genomic data is analyzed for personalized drug development optimization.
|
|
| Locked | Locked | Locked |
Developer of semiconductor biosensor technology
|
Detailed competitors of Nanopath
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nanopath
Complete news archive for Nanopath
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nanopath
Nanopath was founded in 2019 and raised its 1st funding round 3 years after it was founded.
Nanopath is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Alison Burklund is the current CEO of Nanopath. They have also founded this company.
Nanopath is a funded company, having raised a total of $10M across 5 funding rounds to date.
Nanopath was founded in 2019 and is based in Cambridge, United States. A nanotechnology-based platform for point-of-care molecular diagnostics in womens health is developed and offered. Assay development is focused on pelvic and gynecologic infections to enhance patient outcomes through improved diagnostic processes. Operations center on advancing the sectors diagnostic capabilities in a clinical setting.
Nanopath offers Molecular Diagnostic Platform.
Nanopath has 8 investors. Key investors include NIH, Norwest Venture Partners, National Science Foundation, SV Health Investors, and GingerBread Capital.